PEACH
Phase 1 Terminated
3 enrolled 12 charts
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Phase 1 Terminated
132 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled 43 charts
MAST
Phase 1 Terminated
66 enrolled
Breast-48
Phase 1 Terminated
13 enrolled 10 charts
MESO-PRIME
Phase 1 Terminated
5 enrolled 13 charts
PRIMING
Phase 1 Terminated
2 enrolled 10 charts
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
C-TIL051 in Non-Small Cell Lung Cancer
Phase 1 Terminated
1 enrolled
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Phase 1 Terminated
6 enrolled 11 charts
A Study of ASP1012 in Adults With Solid Tumors
Phase 1 Terminated
15 enrolled
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
Phase 1 Terminated
34 enrolled
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
Phase 1 Terminated
212 enrolled
SABRseq
Phase 1 Terminated
13 enrolled 14 charts
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
Phase 1 Terminated
96 enrolled
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Phase 1 Terminated
8 enrolled 8 charts
MK-2118-001
Phase 1 Terminated
140 enrolled 37 charts
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Phase 1 Terminated
221 enrolled
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Phase 1 Terminated
17 enrolled
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
Phase 1 Terminated
16 enrolled 13 charts
RAPTOR
Phase 1 Terminated
27 enrolled
FORTITUDE-201
Phase 1 Terminated
74 enrolled 22 charts
A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
Phase 1 Terminated
2 enrolled 9 charts
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
Phase 1 Terminated
26 enrolled 23 charts
STARLING
Phase 1 Terminated
31 enrolled
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Phase 1 Terminated
47 enrolled
V941-001
Phase 1 Terminated
70 enrolled 18 charts
FPT155-001
Phase 1 Terminated
80 enrolled 49 charts
MK-8353-013
Phase 1 Terminated
111 enrolled 30 charts
V938-001
Phase 1 Terminated
35 enrolled 21 charts
MK-5618-001
Phase 1 Terminated
32 enrolled 17 charts
A Study of ASP1951 in Subjects With Advanced Solid Tumors
Phase 1 Terminated
119 enrolled
PDL1x41BB
Phase 1 Terminated
160 enrolled
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
Phase 1 Terminated
8 enrolled 11 charts
CISPD-2
Phase 1 Terminated
8 enrolled
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1 Terminated
7 enrolled
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Phase 1 Terminated
7 enrolled
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1 Terminated
127 enrolled
A Study of PY314 in Subjects With Advanced Solid Tumors
Phase 1 Terminated
86 enrolled
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
1 enrolled 2 charts
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
NEON-2
Phase 1 Terminated
29 enrolled
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Phase 1 Terminated
13 enrolled
First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors
Phase 1 Terminated
33 enrolled
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Phase 1 Terminated
27 enrolled
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Phase 1 Terminated
87 enrolled
TORCH
Phase 1 Terminated
10 enrolled
A Safety Study of YQ23 in Advanced Solid Tumors Patients
Phase 1 Terminated
3 enrolled
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase 1 Terminated
4 enrolled